2018;391:748 –57. 18. Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, et al. Updated ef ﬁcacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol.2018;13:1156 –70. 19. Gadducci A, Cosio S, Conte PF, Genazzani AR. Consolidation and maintenance treatments for patients with advanced epithelialovarian cancer in complete response after ﬁrst-line chemotherapy: a review of the literature. Crit Rev Oncol/Hematol. 2005;55:153 –66. 20. Gadducci A, Sartori E, Maggino T, Zola P, Landoni F, Fanucchi A, et al. Analysis of failures after negative second-look in patientswith advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol. 1998;68:150 –5. 21. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel- based chemotherapy: a Southwest Oncology Group and Gyne-cologic Oncology Group trial. J Clin Oncol. 2003;21:2460 –5. 22. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primarytreatment of ovarian cancer. N. Engl J Med. 2011;365:2473 –83. 23. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo- controlled phase III trial of chemotherapy with or without bev-acizumab in patients with platinum-sensitive recurrent epithelialovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol.